-
I646492-1mgIL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic
-
I646492-5mgIL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic
-
I649244-10mgIL-17 modulator 3 is an IL-17 modulator (US20200247785A1). IL-17 modulator 3 can be used for the research of inflammation, cancer and autoimmune diseasesForm:SolidIC50& Target:IL-17
-
I649244-1mgIL-17 modulator 3 is an IL-17 modulator (US20200247785A1). IL-17 modulator 3 can be used for the research of inflammation, cancer and autoimmune diseasesForm:SolidIC50& Target:IL-17
-
I649244-5mgIL-17 modulator 3 is an IL-17 modulator (US20200247785A1). IL-17 modulator 3 can be used for the research of inflammation, cancer and autoimmune diseasesForm:SolidIC50& Target:IL-17
-
I647416-10mgIL-17 modulator 4 is a proagent of IL-17 modulator 1 ( HY-141535 ). IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulatorForm:SolidIC50& Target:IL-17
-
I647416-1mgIL-17 modulator 4 is a proagent of IL-17 modulator 1 ( HY-141535 ). IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulatorForm:SolidIC50& Target:IL-17
-
I647416-5mgIL-17 modulator 4 is a proagent of IL-17 modulator 1 ( HY-141535 ). IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulatorForm:SolidIC50& Target:IL-17
-
-
-
I647188-100mgIL-17A antagonist 1 (compound 1) is an IL-17A antagonist, with a K d of 0.66 μM and an IC 50 of 1.14 μMForm:SolidIC50& Target:IL-17A 1.14 nM (IC 50 ) IL-17A 0.66 μM (Kd)
-
I647188-10mgIL-17A antagonist 1 (compound 1) is an IL-17A antagonist, with a K d of 0.66 μM and an IC 50 of 1.14 μMForm:SolidIC50& Target:IL-17A 1.14 nM (IC 50 ) IL-17A 0.66 μM (Kd)